Abstract
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and
pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change
from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.
